Literature DB >> 16958602

Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patients.

Malgorzata Fuksiewicz1, Janina Kaminska, Beata Kotowicz, Maria Kowalska, Maryna Rubach, Tadeusz Pienkowski.   

Abstract

BACKGROUND: The aim of this study was to assess the correlation between serum concentrations of cytokines and soluble cytokine receptors in breast cancer patients and the expression of estrogen and progesterone receptors in tumor cells.
METHODS: The study comprised 158 female breast cancer patients before treatment and 50 healthy individuals as a reference group.
RESULTS: The study revealed significantly higher concentrations of most cytokines in breast cancer patients compared to the reference group. Assessment of the correlation between cytokine concentrations in serum and the expression of estrogen and progesterone receptors in tumor cells showed significantly higher interleukin-8 (IL-8) concentrations in patients lacking progesterone receptors in comparison to patients with these receptors. The concentrations of cytokines and their soluble receptors as a function of the expression of estrogen and progesterone receptors were also analyzed in two age groups. In younger patients, aged 50 years and below, no significant differences were found between serum cytokine concentrations and the expression of both estrogen and progesterone receptors. In patients older than 50 years, significantly higher IL-8 concentrations were observed in individuals lacking progesterone receptors, whereas IL-1ra was significantly higher in those lacking estrogen receptors.
CONCLUSIONS: IL-1ra and IL-8 concentrations in serum, together with a lack of estrogen and progesterone receptors in tumor cells, in breast cancer patients older than 50 years could represent additional predictive factors for this disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16958602     DOI: 10.1515/CCLM.2006.192

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  8 in total

1.  Clinical utility of serum Interleukin-1 receptor antagonist levels as a diagnostic and prognostic assay in surgical patients.

Authors:  Shailendra Kapoor
Journal:  Langenbecks Arch Surg       Date:  2008-09-30       Impact factor: 3.445

2.  Effect of serum interleukin-1 receptor antagonist level on survival of patients with non-small cell lung cancer.

Authors:  Murat Yigit; Serkan Değirmencioğlu; Erhan Ugurlu; Arzu Yaren
Journal:  Mol Clin Oncol       Date:  2017-03-15

Review 3.  Chemokines: novel targets for breast cancer metastasis.

Authors:  Simi Ali; Gwendal Lazennec
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

Review 4.  Why not treat human cancer with interleukin-1 blockade?

Authors:  Charles A Dinarello
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

5.  Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer.

Authors:  Paul J Mills; Sonia Ancoli-Israel; Barbara Parker; Loki Natarajan; Suzi Hong; Shamini Jain; Georgia R Sadler; Roland von Känel
Journal:  Brain Behav Immun       Date:  2007-08-15       Impact factor: 7.217

6.  [Overexpression of IL-8 and MMP-9 confer high malignant phenotype in patients with non-small cell lung cancer].

Authors:  Zhidong Liu; Shaofa Xu; Ning Xiao; Changxing Song; Haiqing Zhang; Fugen Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-08

7.  Preparation, characterization, and evaluation of antitumor effect of Brucea javanica oil cationic nanoemulsions.

Authors:  Ting-Ting Liu; Li-Qiu Mu; Wei Dai; Chuan-Bang Wang; Xin-Yi Liu; Da-Xiong Xiang
Journal:  Int J Nanomedicine       Date:  2016-06-02

8.  Investigation of the Antitumor Effects of Tamoxifen and Its Ferrocene-Linked Derivatives on Pancreatic and Breast Cancer Cell Lines.

Authors:  Márton Kalabay; Zsófia Szász; Orsolya Láng; Eszter Lajkó; Éva Pállinger; Cintia Duró; Tamás Jernei; Antal Csámpai; Angéla Takács; László Kőhidai
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.